

# Supplemental Digital Content

**Figure S1: Model schematic for the phenotype-specific HF models (HF LVEF>40% and HFrEF)**



*Abbreviations: CSS = clinical summary score; CV = cardiovascular; HFrEF, heart failure with reduced ejection fraction; HF LVEF >40%, heart failure with >40% ejection fraction; hHF = hospitalisation due to heart failure;* *KCCQ = Kansas City Cardiomyopathy Questionnaire*

**Figure S2. Overview of the approach used to combine the PSA results of the phenotype-specific HF models**



*Abbreviations: CEM, cost-effectiveness model; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HF LVEF >40%, heart failure with >40% ejection fraction; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year; SoC, standard of care.*

**Table S1.** Details of the subgroup analyses

|  |  |
| --- | --- |
| **Subgroup** | **Description** |
| T2DM at baseline | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population with T2DM at trial entry. |
| No T2DM at baseline | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population without T2DM at trial entry. |
| Baseline age < 65 years | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population younger than 65 years of age. |
| Baseline age ≥ 65 years | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population at least 65 years of age. |
| Baseline eGFR < 60 mL/min/1.73m2 | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population with an eGFR less than 60 mL/min/1.73m2. |
| Baseline eGFR ≥ 60 mL/min/1.73m2 | Adjust mean patient characteristics to reflect subset of EMPEROR-Reduced and EMPEROR-Preserved population with an eGFR of at least 60 mL/min/1.73m2. |

Abbreviations: eGFR, estimated glomerular filtration rate; T2DM, Type II Diabetes Mellitus

**Table S2.** Breakdown of deterministic average costs per patient for the overall HF population

| **Disaggregated costs** | **Empagliflozin + SoC** | **SoC** | **Incremental** |
| --- | --- | --- | --- |
| **Drug acquisition** | £3,998 | £2,382 | £1,616 |
| **hHF management** | £2,686 | £3,108 | -£422 |
| **CV death management** | £2,072 | £2,121 | -£49 |
| **AE management** | £1,698 | £1,708 | -£11 |
| **Disease management** | £4,792 | £4,663 | £130 |
| **Total** | £15,246 | £13,982 | £1,264 |

Note: sums may not add due to rounding

Abbreviations: AE, adverse events; CV, cardiovascular; HF, heart failure; hHF, hospitalization for heart failure; SoC, standard of care

**Table S3**. PSA outcomes for the overall HF population

| **Cost-effectiveness measures** | **Mean** | **Lower 95% CI** | **Upper 95% CI** |
| --- | --- | --- | --- |
| **Incremental LYs** | 0.15 | -0.24 | 0.60 |
| **Incremental QALYs** | 0.16 | -0.16 | 0.52 |
| **Incremental costs** | £1,262 | £201 | £2,148 |
| **ICER (cost/LY gained)** | £8,395 | | |
| **ICER (cost/QALY gained)** | £7,657 | | |

Note: sums may not add due to rounding

Abbreviations: CI, confidence interval; LY, life-year; HF, heart failure; QALY, quality-adjusted life-year; PSA, probabilistic sensitivity analysis

**Table S4.** Scenario analysis (equal split [50%] between the HFrEF and HF LVEF>40%) cost-effectiveness results for the overall HF population

| **Outcome (per patient)** | **Empagliflozin + SoC** | **SoC** | **Incremental** |
| --- | --- | --- | --- |
| **Total discounted LYs** | 6.34 | 6.21 | 0.13 |
| **Total discounted QALYs** | 4.03 | 3.88 | 0.14 |
| **Total discounted costs** | £14,191 | £12,887 | £1,304 |
| **ICER (cost/LY gained)** | £10,208 | | |
| **ICER (cost/QALY gained)** | £9,074 | | |

Note: sums may not add due to rounding

Abbreviations: ICER, incremental cost-effectiveness ratio; LY, life-years; QALY, quality-adjusted life-year

**Table S5.** Scenario analysis (equal split between the HFrEF and HF LVEF>40%) breakdown of average costs per patient for the overall HF population

| **Disaggregated costs** | **Empagliflozin + SoC** | **SoC** | **Incremental** |
| --- | --- | --- | --- |
| **Drug acquisition** | £3,806 | £2,171 | £1,635 |
| **hHF management** | £2,389 | £2,755 | -£366 |
| **CV death management** | £1,897 | £1,950 | -£53 |
| **AE management** | £1,737 | £1,752 | -£15 |
| **Disease management** | £4,362 | £4,259 | £103 |
| **Total** | £14,191 | £12,887 | £1,304 |

Note: sums may not add due to rounding

Abbreviations: AE, ad